Two primary, promising drugs for pancreatic cancer are being developed by Revolution Medicines and a partnership between BioNTech and Genentech. These treatments, \[daraxonrasib\] and an mRNA vaccine, have shown significant potential in improving survival rates for patients with advanced disease.
These developments are being hailed as potential "practice-changing" outcomes for a disease that has historically had few effective treatment options.